Correction to: Nature Biotechnology https://doi.org/10.1038/s41587-019-0023-4, published online 4 February 2019.
In the version of this article initially published, a GlaxoSmithKline compound referred to as GSK298559 was listed in Table 1 as a RIPK1 inhibitor in phase 1 trials for inflammatory bowel disease. The correct designation is GSK2983559; however, this compound is a RIPK2 inhibitor and thus should not have been included in the table in question. The table row has been deleted. The error has been corrected in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sheridan, C. Publisher Correction: Death by inflammation: drug makers chase the master controller. Nat Biotechnol 37, 480 (2019). https://doi.org/10.1038/s41587-019-0082-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-019-0082-6
